{"organizations": [], "uuid": "2d39a661aeaca44e9a8febc5fb31015defc4f36e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-vivus-expands-its-commercial-produ/brief-vivus-expands-its-commercial-product-portfolio-with-the-acquisition-of-pancreaze-idUSASC09YJF", "country": "US", "domain_rank": 408, "title": "BRIEF-Vivus Expands Its Commercial Product Portfolio With The Acquisition Of Pancreaze", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-01T14:09:00.000+03:00", "replies_count": 0, "uuid": "2d39a661aeaca44e9a8febc5fb31015defc4f36e"}, "author": "", "url": "https://www.reuters.com/article/brief-vivus-expands-its-commercial-produ/brief-vivus-expands-its-commercial-product-portfolio-with-the-acquisition-of-pancreaze-idUSASC09YJF", "ord_in_thread": 0, "title": "BRIEF-Vivus Expands Its Commercial Product Portfolio With The Acquisition Of Pancreaze", "locations": [], "entities": {"persons": [{"name": "janssen", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "canada", "sentiment": "none"}], "organizations": [{"name": "vivus inc", "sentiment": "none"}, {"name": "acquisition of pancreaze reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "vivus inc", "sentiment": "none"}, {"name": "vivus", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 1, 2018 / 11:11 AM / a minute ago BRIEF-Vivus Expands Its Commercial Product Portfolio With The Acquisition Of Pancreaze Reuters Staff\nMay 1 (Reuters) - Vivus Inc:\n* VIVUS EXPANDS ITS COMMERCIAL PRODUCT PORTFOLIO WITH THE ACQUISITION OF PANCREAZEÂ®\n* VIVUS - ENTERED INTO AGREEMENT TO BUY ALL PRODUCT RIGHTS FOR PANCREAZE (PANCRELIPASE) DELAYED-RELEASE CAPSULES IN U.S. & CANADA HELD BY JANSSEN PHARMA\n* VIVUS INC - UPON CLOSING, VIVUS WILL ACQUIRE PANCREAZE FROM JANSSEN FOR $135 MILLION. Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-05-01T14:09:00.000+03:00", "crawled": "2018-05-01T14:16:35.067+03:00", "highlightTitle": ""}